化学药制剂

Search documents
天目药业股价震荡下行 成交额突破4亿元
Jin Rong Jie· 2025-08-21 19:50
截至2025年8月21日收盘,天目药业股价报17.50元,较前一交易日下跌1.08元。当日开盘价为19.06元, 最高触及20.44元,最低下探至17.36元,全天振幅达16.58%。成交量为21.65万手,成交金额4.09亿元。 天目药业主要从事中成药、化学药制剂、生物制品等医药产品的研发、生产和销售。公司产品涵盖心脑 血管、抗肿瘤、抗感染等多个治疗领域。 8月21日盘中,天目药业股价出现快速波动。上午9点39分出现快速反弹,5分钟内涨幅超过2%;但在早 盘9点35分也曾出现快速回调,5分钟内跌幅超过2%。 资金流向方面,8月21日主力资金净流出5072.56万元,占流通市值的2.38%。近五个交易日累计净流出 2391.73万元,占流通市值的1.12%。 风险提示:股市有风险,投资需谨慎。 ...
天目药业股价上涨3.24% 盘中振幅超5%
Jin Rong Jie· 2025-08-15 18:09
Company Overview - Tianmu Pharmaceutical's latest stock price is 15.91 yuan, an increase of 0.50 yuan from the previous trading day [1] - The stock reached a high of 16.18 yuan and a low of 15.35 yuan during the day, with a volatility of 5.39% [1] - The trading volume for the day was 76,644 hands, with a transaction amount of 120 million yuan [1] Business Operations - Tianmu Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and biological products [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-tumor, and anti-infection treatments [1] Market Activity - On August 15, Tianmu Pharmaceutical experienced a rapid decline in the morning session, with a drop of over 2% within five minutes, followed by a gradual recovery [1] - The net outflow of main funds for the day was 4.4846 million yuan, while the cumulative net inflow of main funds over the past five trading days was 13.0701 million yuan [1]
新光药业股价上涨1.26% 盘中振幅达10.76%
Jin Rong Jie· 2025-08-04 17:16
Group 1 - The latest stock price of Xinguang Pharmaceutical is 20.05 yuan, an increase of 0.25 yuan from the previous trading day [1] - The stock opened at 18.86 yuan, reached a high of 20.28 yuan, and a low of 18.15 yuan, with an overall fluctuation of 10.76% throughout the day [1] - The trading volume was 260,458 hands, with a total transaction amount of 491 million yuan [1] Group 2 - Xinguang Pharmaceutical operates in the pharmaceutical manufacturing industry, specifically in the traditional Chinese medicine production sector [1] - The company is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and raw materials [1] - Its product range covers multiple therapeutic areas, including cardiovascular, digestive, and respiratory systems [1] Group 3 - On August 4, the stock experienced a rapid rebound during the morning trading session, with a rise of over 2% within 5 minutes [1] - As of 9:37 AM, the stock price was reported at 18.95 yuan, with a transaction amount reaching 105 million yuan [1] - In terms of capital flow, there was a net outflow of 4.5732 million yuan from the main funds on that day, accounting for 0.2% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 22.5547 million yuan, representing 0.99% of the circulating market value [1]
广州医药挂牌新三板,曾折戟港股IPO
Xin Jing Bao· 2025-05-20 08:20
Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].